X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SRP 3D (diethylamide) is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities. It is being evaluated in phase 1 clinical trials for the treatment of acute pain.
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP 3D
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities and is being developed for the treatment of acute pain.
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
The funding Validates the Business Case and Commercial Opportunity of SRP-001 (diethylamide), a first-in-class, novel, non-opioid small molecule analgesic for Acute and Chronic Pain.
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Health
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Funding September 21, 2023
Details:
SRP-001 (diethylamide) is a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics.
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
SRP-001 is an AM404 agonist that targets the endocannabinoid (CB1) pain receptors in the brain,for the treatment of acute and chronic pain,is currently being investigated in a two-part, double-blind, placebo-controlled Phase 1 study.
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
SRP-001, is novel acetaminophen analog with unique mechanism of action for its lack of liver toxicity present in acetaminophen. In development to treat acute and other forms of pain, demonstrates that SRP-001 offers a compelling safety profile over available pain medications
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
